Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 8/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | TP53 | P04637 | 4/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10823736 | 0.84 | NPC1 (0.54) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL562259 | 0.82 | FLT3 (0.46) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL13652067 | 0.82 | SMN1; SMN2 (0.64) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL3867380 | 0.81 | TAS1R3 (0.51) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL3800547 | 0.81 | NPC1 (0.51) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL3794175 | 0.79 | NPC1 (0.50) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL28563825 | 0.79 | SMN1; SMN2 (0.74) | NPC1RAB9ASMN1; SMN2PKMMEN1 | |
| SCHEMBL5613922 | 0.79 | HPGD (0.53) | FLT3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL1059656 | 0.79 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2TP53PKM | |
| SCHEMBL3871617 | 0.79 | TAS1R3 (0.49) | FLT3NPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0779291-B1 | Heterocyclylcarbonyl substituted benzofuranyl-ureas | BAYER AG (DE) | 2001-10-10 | — | — | EP | claimed |
| US-5922740-A | ANTIINFLAMMATORY AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-13 | — | — | US | claimed |
| EP-0779291-A1 | Heterocyclylcarbonyl substituted benzofuranyl-ureas | BAYER AG (DE) | 1997-06-18 | — | — | EP | claimed |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | PALATIN TECHNOLOGIES INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | PALATIN TECHNOLOGIES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-2504352-B1 | MELANOCORTIN-1 RECEPTOR-SPECIFIC CYCLIC PEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-10106578-B2 | Melanocortin-1 receptor-specific linear peptides | PALATIN TECHNOLOGIES, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-10017539-B2 | Melanocortin-1 receptor-specific cyclic hexapeptides | PALATIN TECHNOLOGIES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | PALATIN TECHNOLOGIES INC (US) | 2018-05-31 | — | — | US | disclosed |
| US-20170145056-A1 | Melanocortin-1 Receptor-Specific Linear Peptides | PALATIN TECHNOLOGIES INC (US) | 2017-05-25 | — | — | US | disclosed |
| EP-0779291-B1 | Heterocyclylcarbonyl substituted benzofuranyl-ureas | BAYER AG (DE) | 2001-10-10 | — | — | EP | disclosed |
| US-6277878-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | PFIZER INC | 2001-08-21 | — | — | US | disclosed |
| EP-0985666-A1 | Substituted indole compounds as COX-2 inhibitors | PFIZER INC. (US) | 2000-03-15 | — | — | EP | disclosed |
| US-5922740-A | ANTIINFLAMMATORY AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-13 | — | — | US | disclosed |
| US-5922740-A | ANTIINFLAMMATORY AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-13 | — | — | US | disclosed |
| US-5922740-A | ANTIINFLAMMATORY AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-13 | — | — | US | disclosed |
| EP-0779291-A1 | Heterocyclylcarbonyl substituted benzofuranyl-ureas | BAYER AG (DE) | 1997-06-18 | — | — | EP | disclosed |
| EP-0779291-A1 | Heterocyclylcarbonyl substituted benzofuranyl-ureas | BAYER AG (DE) | 1997-06-18 | — | — | EP | disclosed |
| EP-0779291-A1 | Heterocyclylcarbonyl substituted benzofuranyl-ureas | BAYER AG (DE) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | MC1R, MC3R, MC4R | FLT3 2025/4885NPC1 1411/4885RAB9A 211/4885 |
| US-10106578-B2 | Melanocortin-1 receptor-specific linear peptides | MC1R, MC5R, MC3R | FLT3 1589/4885NPC1 3648/4885RAB9A 1451/4885 |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | FLT3 1496/4885NPC1 3165/4885RAB9A 1797/4885 |
| US-10017539-B2 | Melanocortin-1 receptor-specific cyclic hexapeptides | MC1R, MC3R, MC5R | FLT3 786/4885NPC1 2800/4885RAB9A 287/4885 |
| US-20170145056-A1 | Melanocortin-1 Receptor-Specific Linear Peptides | MC1R, MC5R, MC3R | FLT3 1589/4885NPC1 3648/4885RAB9A 1451/4885 |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | MC3R, MC1R, MC2R | FLT3 1496/4885NPC1 3165/4885RAB9A 1797/4885 |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | MC1R, MC3R, MC4R | FLT3 2025/4885NPC1 1411/4885RAB9A 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.